Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Change in Acquisitions & Divestments: 2009-2018

Historic Change in Acquisitions & Divestments for Ironwood Pharmaceuticals (IRWD) over the last 10 years, with Dec 2018 value amounting to $99.2 million.

  • Ironwood Pharmaceuticals' Change in Acquisitions & Divestments fell 28.48% to $19.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was $99.2 million, marking a year-over-year decrease of 71.41%. This contributed to the annual value of $99.2 million for FY2018, which is 71.41% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Change in Acquisitions & Divestments of $99.2 million as of FY2018, which was down 71.41% from $346.9 million recorded in FY2017.
  • Over the past 5 years, Ironwood Pharmaceuticals' Change in Acquisitions & Divestments peaked at $346.9 million during FY2017, and registered a low of $99.2 million during FY2018.
  • For the 3-year period, Ironwood Pharmaceuticals' Change in Acquisitions & Divestments averaged around $227.8 million, with its median value being $237.4 million (2016).
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Change in Acquisitions & Divestments skyrocketed by 46.11% in 2017, and later plummeted by 71.41% in 2018.
  • Over the past 5 years, Ironwood Pharmaceuticals' Change in Acquisitions & Divestments (Yearly) stood at $201.0 million in 2014, then spiked by 37.69% to $276.7 million in 2015, then declined by 14.20% to $237.4 million in 2016, then skyrocketed by 46.11% to $346.9 million in 2017, then tumbled by 71.41% to $99.2 million in 2018.